Articles written by Vandana Singh - Benzinga

Eli Lilly Stock Offers Buying Opportunity For Goldman Sachs. Concerns Over CVS Setback Are Overblown, Analysts Say

Eli Lilly's Zepbound loses CVS coverage to Wegovy, prompting analyst debate on pricing pressures and long-term obesity market potential.

Why Is Novo Nordisk Stock Trading Higher On Friday?

Health Canada begins a priority review of semaglutide 2.4 mg, a weekly treatment by Novo Nordisk for MASH, a liver disease affecting patients with obesity.

Drug Maker Amneal Highlights Strong Commercial Uptake For Parkinson's Drug But Q1 Earnings Are Mixed

Amneal Pharmaceuticals reported first-quarter 2025 adjusted earnings per share of 21 cents, up from 14 cents a year ago.

Zio Demand Drives 20% Revenue Growth For iRhythm, Bullish Sentiment Builds Among Analysts

iRhythm raises 2025 sales forecast and launches Zio ECG system in Japan as analysts boost ratings and price targets on strong Q1 performance.

AstraZeneca's Triple-Combination Therapy Breztri Hits Primary Goals In Two Pivotal Studies For Asthma

AstraZeneca's Breztri met primary goals in four asthma trials, including KALOS, LOGOS, LITHOS, and VATHOS, involving over 5,000 patients.

Cigna CEO Says Strong Q1 Earnings, Increased Outlook Reflect Strength In Growth Platforms

Cigna posts strong Q1 results with rising sales at Evernorth and Cigna Healthcare; raises 2025 EPS outlook to $29.60 amid higher medical cost ratio expectations.

Cancer Diagnostic Firm Exact Sciences' CEO Says Strong Q1 Paves Way For 'Transformative' 2025, Lifts Annual Guidance

Exact Sciences posted better-than-expected Q1 results and lifted its 2025 outlook, signaling confidence in growth and operational momentum.

Cardinal Health Lifts FY25 EPS Outlook, Sees Growth Despite Tariff Risks

Cardinal Health raised FY25 EPS guidance after Q3 profit gains in key segments, while revenue slightly missed estimates amid contract expirations.

Biogen Beats Q1 Earnings Expectations As Two Newcomer Drug Sales Spike, Avoids Tariff Impact

Biogen beat Q1 earnings and revenue estimates, raised rare disease drug sales, and cut its 2025 EPS guidance due to a $165 million collaboration payment.

GE HealthCare's Strong Q1 Took Back Seat To Tariffs, Analyst Sees 2026 Tariff Impact Less Than 2025

GE HealthCare beats Q1 estimates and sees strong order growth, but tariff concerns prompt analysts to cut price targets despite a positive outlook.

CVS Caremark To Place Novo Nordisk's Wegovy On Preferred Coverage For GLP-1 Weight Loss Treatment

Wegovy to become preferred GLP-1 drug on CVS Caremark's top formularies in 2025 as Novo Nordisk expands patient access initiatives.

Moderna Expands Cost-Cutting Program By Up To $1.7 Billion, FDA Approval For Flu/COVID-19 Combo Shot Delayed Into 2026

Moderna reaffirms 2025 revenue guidance of $1.5 billion–$2.5 billion, cuts 2027 cost forecast by up to $1.7 billion, and targets 2026 approval for its flu/COVID combo shot.

Baxter Reports Strong Medical Devices Sales In Q1, Lifts 2025 Guidance, Stock Jumps

Baxter raised its 2025 outlook after strong Q1 results, citing robust growth in infusion therapies and advanced surgery.

CVS Health Partners With Wegovy Maker Novo Nordisk, Hikes 2025 Guidance

CVS Health topped Q1 estimates with $94.59 billion in revenue and raised 2025 EPS outlook to $6.00–$6.20 amid strong Medicare performance.

Potential Tariff Bites Into Becton Dickinson 2025 Profit Outlook, Company Will Invest $2.5 Billion To Boost US Manufacturing

Becton Dickinson trims 2025 EPS outlook on tariffs, reports Q1 sales miss, and confirms $2.5B U.S. manufacturing investment over 5 years.

Mounjaro Maker Eli Lilly Clocks 45% Jump In Q1 Revenue, Cuts 2025 Profit Outlook But Not Due To Tariffs

Eli Lilly cut its 2025 profit outlook after strong Q1 sales from Mounjaro and Zepbound and a $1.57 billion charge tied to a cancer drug acquisition.

EXCLUSIVE: TransCode Therapeutics Reports Progress In Early-Stage Study For Lead Cancer Drug

TransCode Therapeutics advances Phase 1a trial of TTX-MC138 for metastatic cancer with early signs of stability and consistent PK/PD data.

EXCLUSIVE: Adial Pharmaceuticals Expands Patent Portfolio With New US Patent For Lead Drug For Alcohol And Opioid Use Disorders

Adial secures USPTO patent for AD04, expanding coverage to treat alcohol and opioid-related disorders in patients with genetic markers.

Abeona Surges After FDA Clears First Gene Therapy For Severe Genetic Skin Disease

Abeona's Zevaskyn secures timely FDA nod, priced at $3.1 million, with 2025 sales now forecast at $31.6 million and peak U.S. revenue projected at $600 million.

Dallas Fed Flags Deepening Factory Gloom: Is Texas Warning Of Something Bigger?

SEO-Optimized Meta Description (Under 156 Characters): Texas manufacturing conditions worsened in April as business sentiment plunged, tariff fears grew, and price pressures surged, Dallas Fed survey shows.